The New England journal of medicineAgedFemaleHumansMaleMiddle Aged
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.
Erin A Bohula, Nicholas A Marston, Ajay K Bhatia, Gaetano M De Ferrari, Lawrence A Leiter, Jose C Nicolau, Jeong-Gun Park, Julia F Kuder, Sabina A Murphy, Emileigh Walsh, Huei Wang, Vladimir Blaha, Andrzej Budaj, Jan H Cornel, Assen Goudev
Published: 202610.1056/NEJMoa2514428
Abstract
BACKGROUND: The proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor evolocumab reduces the risk of major adverse cardiovascular events (MACE) among patients with a previous myocardial infarction, stroke, or symptomatic peripheral artery d…
Preview only. Read the full abstract at the source